| Impact Factor 18.786 * | In this issue
  Editorial
Research Highlights
News and Views
Reviews
Perspectives
Also this month
 Featured article:
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Celine Boutros, Ahmad Tarhini, Emilie Routier, Olivier Lambotte, Francois Leroy Ladurie, Franck Carbonnel, Hassane Izzeddine, Aurelien Marabelle, Stephane Champiat, Armandine Berdelou, Emilie Lanoy, Matthieu Texier, Cristina Libenciuc, Alexander M. M. Eggermont, Jean-Charles Soria, Christine Mateus & Caroline Robert |
|
| |
 | | | | | | | | NEWS AND VIEWS | Top | Gastrointestinal cancer: Light and shade of intrahepatic arterial radiotherapy in mCRC
Josep Tabernero & Ramon Salazar
Published online: 14 June 2016
p467 | doi:10.1038/nrclinonc.2016.92
The results of a number of studies have demonstrated the promise of adding intrahepatic arterial selective internal radiotherapy (SIRT) to chemotherapy for patients with liver metastases from colorectal cancer; however, the frequent progression of extrahepatic metastases observed in patients treated with SIRT in the SIRFLOX trial call the potential overall benefit of this approach into question.
Full Text | PDF
| Paediatrics: Metronomics — fulfilling unmet needs beyond level A evidence
Nicolas André, Shripad Banavali & Eddy Pasquier
Published online: 28 June 2016
p469 | doi:10.1038/nrclinonc.2016.102
To improve the survival rates globally for paediatric patients with cancer, looking beyond level A evidence to treat children in low and middle-income countries is imperative. Herein, we discuss why metronomic chemotherapy, which is less toxic and more affordable, offers a pragmatic approach to provide new standards for patients with relapsed disease who have no alternatives.
Full Text | PDF
| Breast cancer: The 21-gene recurrence score — biology remains at the forefront
Shannon L. Puhalla & Nancy E. Davidson
Published online: 14 June 2016
p470 | doi:10.1038/nrclinonc.2016.98
The 21-gene recurrence score is a genetic assay developed to estimate the likelihood of distant recurrence in patients with oestrogen-receptor-positive, lymph-node-negative breast cancer treated with adjuvant endocrine therapy. Now, two studies explore how the 21-gene recurrence score has been used to inform treatment decisions in this setting and beyond.
Full Text | PDF
| | | | | | REVIEWS | Top | Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Celine Boutros, Ahmad Tarhini, Emilie Routier, Olivier Lambotte, Francois Leroy Ladurie, Franck Carbonnel, Hassane Izzeddine, Aurelien Marabelle, Stephane Champiat, Armandine Berdelou, Emilie Lanoy, Matthieu Texier, Cristina Libenciuc, Alexander M. M. Eggermont, Jean-Charles Soria, Christine Mateus & Caroline Robert
Published online: 04 May 2016
p473 | doi:10.1038/nrclinonc.2016.58
Immune checkpoint inhibition is a novel approach to cancer treatment with enormous potential to improve the outcomes of patients with a range of malignancies. However, owing to this novel approach, a range of adverse events have emerged with different aetiologies to those of more conventional cancer treatments. In this Review, the authors describe the occurrence, and optimal management of adverse events resulting from use of immune checkpoint inhibitors.
Abstract | Full Text | PDF | Supplementary information
| Biomarkers of residual disease after neoadjuvant therapy for breast cancer
Frederique Penault-Llorca & Nina Radosevic-Robin
Published online: 09 February 2016
p487 | doi:10.1038/nrclinonc.2016.1
The pathobiological features of the breast cancer tissue that remains present after neoadjuvant therapy (NAT) are a major determinant of patient outcome. The decision to further treat this residual disease has traditionally been guided by the features of the tumour at diagnosis, but substantial biological differences exist between treatment-naive breast cancer and the post-NAT residual tissue. In this Review, the authors describe how the evaluation of the response of breast tumours to neoadjuvant treatment should be standardized, and provide an overview of potential biomarkers of prognosis.
Abstract | Full Text | PDF
| Diet, nutrition, and cancer: past, present and future
Susan T. Mayne, Mary C. Playdon & Cheryl L. Rock
Published online: 08 March 2016
p504 | doi:10.1038/nrclinonc.2016.24
Diet has long been linked with the development and progression of cancer, and indeed obesity is a clear risk factor for many cancers; however, teasing out the relationships between nutritional factors and cancer aetiology has proved difficult, complicating the development of dietary recommendations for cancer prevention. In this Review, the issues and challenges in diet-cancer research are discussed, including those relating to the design of epidemiological studies, dietary data collection methods, and factors that affect the outcome of intervention trials.
Abstract | Full Text | PDF
| | | | | | PERSPECTIVES | Top | OPINION
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
Michael B. Bernstein, Sunil Krishnan, James W. Hodge & Joe Y. Chang
Published online: 08 March 2016
p516 | doi:10.1038/nrclinonc.2016.30
Substantial interest exists in the effects of immunotherapy; however, radiation therapy also has the potential to stimulate an antitumour immune response. In this Perspectives, the authors describe the rationale for combining immunotherapy with stereotactic ablative radiotherapy based on the available clinical data, and provide recommendations for the future testing of approaches using this combination of treatments.
Abstract | Full Text | PDF
| | | | Advertisement | | Bone Research is an open access, peer-reviewed journal which publishes the best and most interesting research focusing on basic and clinical aspects of bone biology, pathophysiology and regeneration, and supports the foremost discoveries resulting from basic investigations and clinical research related to bone.
Submit your manuscript. |  | | | | | | | | | | | | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com | | | | | |
|
| *Journal Citation Reports, Thomson, 2016. Nature Reviews Clinical Oncology was previously published as Nature Clinical Practice Oncology. |
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. |
 |
|
No comments:
Post a Comment
Keep a civil tongue.